Startups
MedAlliance is a privately-owned medical technology company, developing ground-breaking technology f
Overview
Location
Switzerland, Vaud, Nyon
Employees
51-200
Phone
+41 22 363 78 90
Total raised
$50M
Founded date
2008
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 33
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 2, 2023 | MedAlliance Acquired by Cordis for USD 1.135 Billion | GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones o... |
| Sep 15, 2023 | MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study | GENEVA, Sept. 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNo... |
| Sep 6, 2023 | MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study | GENEVA, Sept. 6, 2023 /PRNewswire/ -- The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh... |
| Aug 16, 2023 | MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients | GENEVA, Aug. 16, 2023 /PRNewswire/ -- MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in re... |
| May 31, 2023 | Excellent 12-Month Results from SELUTION SFA Trial Presented at JET | GENEVA, May 31, 2023 /PRNewswire/ -- 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTI... |
| May 5, 2023 | MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA | GENEVA, May 5, 2023 /PRNewswire/ -- The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR™ in the treatment of ... |
| Mar 15, 2023 | Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study | GENEVA, March 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients.... |
| Jan 26, 2023 | MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study | GENEVA, Jan. 26, 2023 /PRNewswire/ -- The first US patient has been enrolled at MedStar Washington Hospital Center in the SELUTION4ISR study evaluating SELUTION SLR™ to support FDA approval. This milestone follows Investigational Device Exe... |
| Jan 11, 2023 | MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval | GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of cor... |
Show more
Reviews 0
FAQ about MedAlliance Swiss Medical Technology
When was MedAlliance Swiss Medical Technology founded?
MedAlliance Swiss Medical Technology was founded in 2008.
How much funding has MedAlliance Swiss Medical Technology raised?
MedAlliance Swiss Medical Technology has raised $50M in total across 1 funding round.
What has the press written about MedAlliance Swiss Medical Technology?
Parsers VC has collected 33 articles mentioning MedAlliance Swiss Medical Technology, among them “MedAlliance Acquired by Cordis for USD 1.135 Billion” (Oct 2, 2023) and “MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study” (Sep 15, 2023).
Is MedAlliance Swiss Medical Technology still active?
Yes, MedAlliance Swiss Medical Technology is active; its latest activity on Parsers VC dates from Oct 2, 2023.